Enliven Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.95%
vs ±11.2% implied · ×0.08
shaded = implied · ▲▼ = realized
Enliven Therapeutics has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceThe drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.
ELVN 10-Kaccession 0001193125-26-088232
SentenceTo date, we have obtained the custom-manufactured starting materials for active pharmaceutical ingredients ("APIs") manufacture from Pharmaron and Hande Sciences and our good manufacturing practice ("GMP") APIs from Pharmaron.
ELVN 10-Kaccession 0001193125-26-088232
SentenceThe drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.
ELVN 10-Kaccession 0001193125-26-088232
SentenceFor example, we use Pharmaron, located in China, to conduct preclinical studies and clinical trials and provide us with active pharmaceutical ingredients ("APIs").
ELVN 10-Kaccession 0001193125-26-088232
SentenceThe drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.
ELVN 10-Kaccession 0001193125-26-088232
—
—
Enliven Therapeutics, Inc.
44.25
Largest filed tie
—
Expected move
Inputs8Q avg ±3.0%·×2.02·rich
straddle ±10.7%
spot 44.25exp Nov 20ATM strike 45ATM straddle 5.57IV 65%